Dermata Therapeutics Inc
Veridion Score
Composite trend over time
Why is DRMA moving today?
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DRMA.
DRMA insider activity
Dermata Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $1K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-16 | 2026-06-16 | Scott Kathleen D. | Insider | sell | $1.19 | 11 | Not reported | $13 | SEC Form 4 |
| 2026-03-17 | 2026-02-17 | Bedoya-Toro Munera Maria E | Insider | buy | $1.27 | 1,000 | 1,012 | $1K | SEC Form 4 |
DRMA contract awards, year to date.
Public federal awards linked to this ticker.
DRMA lobbying filings, year to date.
Registered lobbying filings matched to Dermata Therapeutics Inc.